Novolog, Novorapid(insulin aspart)
Fiasp, Insulin Aspart, Kirsty, Kixelle, Mix, NovoRapid, Novolog, Novolog Mix, Ryzodeg (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Novorapid on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Fiasp, Novolog
CombinationsNovolog mix (discontinued: Ryzodeg)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin aspart
Insulin aspart
+
Insulin aspart protamine
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Novolog Mix 70/30 | insulin aspart protamine and insulin aspart | Novo Nordisk Inc. | N-21172 RX | 2001-11-01 | 2 products |
Show 2 discontinued
Insulin aspart
+
Insulin degludec
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Ryzodeg 70/30 | insulin degludec and insulin aspart | Novo Nordisk Inc. | N-203313 DISCN | 2015-09-25 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| .insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2021-09-15 |
| .insulin aspart protamine and insulin aspart insulin aspart protamine and insulin aspart | NDA authorized generic | 2019-11-15 |
| fiasp | Biologic Licensing Application | 2022-09-02 |
| insulin aspart | Biologic Licensing Application | 2023-09-18 |
| insulin aspart protamine and insulin aspart | Biologic Licensing Application | 2023-09-28 |
| insulin diluting medium for novolog novolog | Biologic Licensing Application | 2023-02-28 |
| novolog | Biologic Licensing Application | 2023-12-15 |
| novolog mix 70/30 | Biologic Licensing Application | 2024-01-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB05: Insulin aspart
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD05: Insulin aspart
— A10AD06: Insulin degludec and insulin aspart
HCPCS
No data
Clinical
Clinical Trials
596 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 58 | 29 | 55 | 47 | 67 | 252 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 15 | 10 | 66 | 88 | 72 | 249 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 2 | 5 | 11 | 8 | 11 | 33 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | 1 | 1 | 1 | 6 | 6 | 15 |
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | 2 | 2 | 2 | 2 | 1 | 9 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | 1 | 1 | 3 | 1 | 6 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | 1 | 2 | — | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 1 | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | 1 | 2 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes complications | D048909 | — | — | — | 3 | 4 | — | — | 4 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 1 | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 1 | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | — | — | 1 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | — | 1 |
| Puerperal disorders | D011644 | EFO_0009683 | O89 | — | — | 1 | — | — | 1 |
| Pregnancy complications | D011248 | — | — | — | — | 1 | — | — | 1 |
| Wound healing | D014945 | GO_0042060 | — | — | 1 | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | — | — | — | 2 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 1 | — | — | — | 2 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 1 | — | — | — | 2 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | — | — | — | 1 |
| High-risk pregnancy | D018566 | — | — | — | 1 | — | — | — | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | 1 | — | — | — | 1 |
| Therapeutics | D013812 | — | — | — | 1 | — | — | — | 1 |
| Delirium | D003693 | — | R41.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 23 | — | — | — | — | 23 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | 1 | — | — | — | — | 1 |
| Olfaction disorders | D000857 | HP_0000458 | R43.0 | 1 | — | — | — | — | 1 |
| Taste disorders | D013651 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | — | — | — | 3 | 3 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Self efficacy | D020377 | — | — | — | — | — | — | 1 | 1 |
| Congenital hyperinsulinism | D044903 | — | — | — | — | — | — | 1 | 1 |
| Memory disorders | D008569 | — | — | — | — | — | — | 1 | 1 |
| Heart disease risk factors | D000082742 | — | — | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Hemostasis | D006487 | — | — | — | — | — | — | 1 | 1 |
| Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Insulin aspart |
| INN | insulin aspart |
| Description | Insulin aspart |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201496 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01306 |
| UNII ID | D933668QVX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ryzodeg – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Novomix – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Novorapid – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Fiasp – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Insulin aspart
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,398 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,773 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use